Positions

Overview

  • Dr. Lebensburger is the Director, Pediatric Hematology Section in the Division of Pediatric Hematology Oncology. He has expertise in sickle cell disease and hemoglobinopathies, red cell disorders, ITP, bleeding disorders, blood clotting disorders, bone marrow failure syndromes, and general hematology.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Patients with sickle cell disease who develop end-stage kidney disease continue to experience poor survival — A 19-year United States Renal Data System study.  British Journal of Haematology.  199:e43-e47. 2022
    2022 Adverse childhood experiences in children and adolescents with sickle cell disease: A retrospective cohort study.  Pediatric Blood and Cancer.  69. 2022
    2022 Altered mental status as a presentation of rhabdomyolysis in a patient with sickle cell anemia.  Pediatric Blood and Cancer.  69. 2022
    2022 The influence of perceived racial bias and health-related stigma on quality of life among children with sickle cell disease.  Ethnicity and Health.  27:833-846. 2022
    2021 Pain-Related Injustice Appraisals in Youth with Sickle Cell Disease: A Preliminary Investigation.  Pain Medicine.  22:2207-2217. 2021
    2021 Generalization of a genetic risk score for time to first albuminuria in children with sickle cell anaemia: SCCRIP cohort study results.  British Journal of Haematology.  194:469-473. 2021
    2021 Hyperuricemia and abnormal nocturnal dipping impact glomerular filtration rate in patients with sickle cell anemia.  American Journal of Hematology.  96:E143-E146. 2021
    2021 Novel CUBN Mutation in a Young Child with Megaloblastic Anemia.  Journal of Pediatric Hematology/Oncology.  43:E546-E549. 2021
    2021 Acute chest syndrome in pediatric sickle cell disease: Associations with racial composition and neighborhood deprivation.  Pediatric Blood and Cancer.  68. 2021
    2021 Nocturnal hypoxemia measured by polysomnogram is associated with acute chest syndrome in pediatric sickle cell disease 2021
    2021 Xanthine Oxidase Drives Hemolysis and Vascular Malfunction in Sickle Cell Disease 2021
    2021 High bias and low precision for estimated versus measured glomerular filtration rate in pediatric sickle cell anemia.  The hematology journal : the official journal of the European Haematology Association / EHA.  106:295-298. 2021
    2020 Outcomes of isolated neutropenia referred to pediatric hematology-Oncology clinic.  Pediatrics.  146. 2020
    2020 Outpatient pain clinic and intranasal fentanyl to improve sickle cell disease outcomes.  Pediatric Blood and Cancer.  67. 2020
    2020 Roseomonas gilardii Bacteremia in a Patient with HbSβ0-thalassemia: Clinical Implications and Literature Review.  Journal of Pediatric Hematology/Oncology.  42:e385-e387. 2020
    2020 Sex differences in the trajectory of glomerular filtration rate in pediatric and murine sickle cell anemia.  Blood Advances.  4:263-265. 2020
    2019 Effect of Sickle Cell Anemia Therapies on the Natural History of Growth and Puberty Patterns.  Journal of Pediatric Hematology/Oncology.  41:606-611. 2019
    2019 Children with sickle cell anemia and APOL1 genetic variants develop albuminuria early in life.  The hematology journal : the official journal of the European Haematology Association / EHA.  104:E385-E387. 2019
    2019 Hyperfiltration during early childhood precedes albuminuria in pediatric sickle cell nephropathy.  American Journal of Hematology.  94:417-423. 2019
    2019 Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease.  Journal of Allergy and Clinical Immunology.  143:1482-1495. 2019
    2019 American Society of Hematology 2019 guidelines for sickle cell disease: Cardiopulmonary and kidney disease.  Blood Advances.  3:3867-3897. 2019
    2019 End points for sickle cell disease clinical trials: Renal and cardiopulmonary, cure, and low-resource settings.  Blood Advances.  3:4002-4020. 2019
    2019 Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.  American Journal of Hematology.  94:E27-E29. 2019
    2019 Hyperfiltration predicts long-term renal outcomes in humanized sickle cell mice.  Blood Advances.  3:1460-1475. 2019
    2018 Impact of early analgesia on hospitalization outcomes for sickle cell pain crisis.  Pediatric Blood and Cancer.  65. 2018
    2018 Red blood cell transfusion therapy for sickle cell patients with frequent painful events.  Pediatric Blood and Cancer.  65. 2018
    2018 Outcomes of febrile events in pediatric patients with sickle cell anemia.  Pediatric Blood and Cancer.  65. 2018
    2018 Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood.  Pediatric Blood and Cancer.  65. 2018
    2018 Acute kidney injury during parvovirus B19-induced transient aplastic crisis in sickle cell disease.  American Journal of Hematology.  93:E198-E200. 2018
    2018 Management of severe chronic pain with methadone in pediatric patients with sickle cell disease.  Pediatric Blood and Cancer.  65. 2018
    2018 Outcomes in mild to moderate isolated thrombocytopenia.  Pediatrics.  142. 2018
    2018 Hydroxycarbamide for patients with silent cerebral infarcts: outcomes and patient preference.  British Journal of Haematology.  181:145-148. 2018
    2017 Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia.  Pediatric Nephrology.  32:1565-1573. 2017
    2017 Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis.  Pediatric Nephrology.  32:1451-1456. 2017
    2017 Publication outcomes of abstracts from the American Society of Hematology Annual Meeting.  American Journal of Hematology.  92:E81-E83. 2017
    2017 Cranial epidural hematomas: A case series and literature review of this rare complication associated with sickle cell disease.  Pediatric Blood and Cancer.  64. 2017
    2017 Severe anemia early in life as a risk factor for sickle-cell kidney disease.  Blood.  129:385-387. 2017
    2017 Elective cholecystectomy reduces morbidity of cholelithiasis in pediatric sickle cell disease.  Pediatric Blood and Cancer.  64:113-120. 2017
    2016 Absorbance and redox based approaches for measuring free heme and free hemoglobin in biological matrices.  Redox Biology.  9:167-177. 2016
    2016 Prevalence of acute kidney injury during pediatric admissions for acute chest syndrome.  Pediatric Nephrology.  31:1363-1368. 2016
    2016 Maintaining high level of care at satellite sickle cell clinics.  Journal of Health Care for the Poor and Underserved.  27:280-292. 2016
    2015 Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemia.  Journal of Blood Medicine.  6:285-290. 2015
    2015 Systematic review of interventional sickle cell trials registered in ClinicalTrials.gov.  Clinical Trials.  12:575-583. 2015
    2015 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.  Pediatric Blood and Cancer.  62:1427-1436. 2015
    2015 Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease.  Journal of Neurosurgery: Pediatrics.  16:64-73. 2015
    2015 Exploring Adult Care Experiences and Barriers to Transition in Adult Patients with Sickle Cell Disease..  International journal of hematology & therapy.  1. 2015
    2015 Patient-centered approach to designing sickle cell transition education.  Journal of Pediatric Hematology/Oncology.  37:43-47. 2015
    2015 Understanding and improving health education among first-time parents of infants with sickle cell anemia in alabama: A mixed methods approach.  Journal of Pediatric Hematology/Oncology.  37:35-42. 2015
    2014 Ferritin and LIC: Predicting liver injury in children with sickle cell.  Journal of Pediatric Gastroenterology and Nutrition.  58:387-390. 2014
    2014 Social skills and executive function among youth with sickle cell disease: A preliminary investigation.  Journal of Pediatric Psychology.  39:493-500. 2014
    2013 Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea.  Pediatric Blood and Cancer.  60:1333-1337. 2013
    2013 Hydroxyurea treatment of children with hemoglobin SC disease.  Pediatric Blood and Cancer.  60:323-325. 2013
    2012 Influence of severity of anemia on clinical findings in infants with sickle cell anemia: Analyses from the BABY HUG study.  Pediatric Blood and Cancer.  59:675-678. 2012
    2012 Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.  Blood.  119:1915-1921. 2012
    2012 Barriers in transition from pediatrics to adult medicine in sickle cell anemia..  Journal of Blood Medicine.  3:105-112. 2012
    2011 Laboratory and clinical correlates for magnetic resonance imaging (MRI) abnormalities in pediatric sickle cell anemia.  Journal of Child Neurology.  26:1260-1264. 2011
    2011 Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia.  American Journal of Hematology.  86:430-432. 2011
    2011 What is the evidence for using hydroxyurea for secondary stroke prevention?.  Hematology.  2011:440-442. 2011

    Research Overview

  • Dr. Lebensburger is an international expert in sickle cell kidney disease. He has received several prestigious research grants to study sickle cell kidney disease from the National Institutes of Health, American Society of Hematology, Pfizer ASPIRE Sickle Cell. He served on the American Society of Hematology Sickle Cell Guidelines Panel and the American Society of Hematology/Food and Drug Administration, Sickle Cell Trials Clinical Trial Endpoints Workshop. He is also focused on patient centered research including improving patient/parent education and transition of care. He is funded by the Patient Centered Outcomes Research Institute to study sickle cell transition of care. Finally, he has published numerous articles on other sickle cell complications including in stroke and pain. He was an investigator for several leading sickle cell trials.
    He also has a research interest in Immune Thrombocytopenia (ITP)serving as an investigator for the ITP Consortium of North America.

    • Principal Investigator On

  • A Feasibility Trial Using Hydroxyurea for Secondary Prevention of Silent Cerebral Infracts in Children with Sickle Cell Disease  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE
  • A Phase 3 Study of Eltrombopag vs Standard First-Line Management for Newly-Diagnosed Immune Thrombocytopenia (ITP) in Children  awarded by BOSTON CHILDREN'S HOSPITAL
  • APOL1 Gene Variants and ET-1 as Predictors of Sickle Nephropathy  awarded by St. Jude Children's Research Hospital
  • Acute Kidney Injury During Sickle Cell Crisis  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Baby Hug Follow-Up Study II  awarded by University of Texas Southwestern Medical Center at Dallas
  • Chronobiology and Chronopharmacology to Prevent Sickle Cell Nephropathy  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Chronobiology and Chronopharmacology to Prevent Sickle Cell Nephropathy  awarded by American Society of Hematology ^
  • Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children  awarded by Johns Hopkins University
  • Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children  awarded by Johns Hopkins University
  • Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children  awarded by Johns Hopkins University
  • Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Outcomes of Pediatric Patients with Isolated Neutropenia: A Cost-effectiveness Study Involving Limited Red Cell Phenotyping  awarded by American Society of Hematology ^
  • Patient Centered Research to Enhance Transition Education  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE
  • Private Grant  awarded by WYETH PHARMACEUTICALS, INC.
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC.
  • Quality Improvement Pathway for Newly Diagnosed Immune Thrombocytopenia in Children  awarded by BOSTON CHILDREN'S HOSPITAL

    • Investigator On

  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD  awarded by CHILDREN'S ONCOLOGY GROUP
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVANCING ALSTATE (Alabama Lifespan Sickle cell Tracking Access Towards Equality) Network  awarded by CDC - Centers for Disease Control and Prevention/DHHS
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ASH Research Collaborative (ASH RC) Sickle Cell Disease Clinical Trials Network (SCD CTN)  awarded by American Society of Hematology ^
  • Achieving Understanding of the Natural History of Sickle Trait (AUNT)  awarded by NATIONAL ALLIANCE OF SICKLE CELL CENTERS
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Baby HUG Follow-up Study II: Clinical Studies  awarded by University of Texas Southwestern Medical Center at Dallas
  • CCOP Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children  awarded by Johns Hopkins University
  • Interdisciplinary Training In Kidney-Related Research  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Interdisciplinary Training in Kidney-Related Research  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Kidney Undergraduate Research Experience (KURE)  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • NAPAAC Registry Study of Bone Marrow Failure and Myelodysplastic Syndromes  awarded by BOSTON CHILDREN'S HOSPITAL
  • Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors  awarded by University of Wisconsin-Milwaukee
  • PRedOctoral Phd and MD Research Training In TEams (PROmoTE)  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • PRedoctoral Interdisciplinary Training in Renal Physiology and MEdIcIne (PRIME)  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Patient Characteristics and Treatment Patterns from Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis from Select Sickle Cell Centers  awarded by NATIONAL ALLIANCE OF SICKLE CELL CENTERS
  • Pediatric Trial Network-Hydroxyuea/To 4  awarded by Duke University
  • Per Case Reimbursement (PCR)- NIH National Clinical Trails Network (NCTN) Grant (U10CA180886) -PHI/COG  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Private Grant  awarded by GLYCOMIMETICS, INC.
  • Private Grant  awarded by TERUMO BCT, INC.
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Transforming Pediatric Oncology Healthcare Through Family Navigation  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION

    • Teaching Overview

  • Dr. Lebensburger teaches a wide array of courses in Hematology to Medical students, Pediatric residents, and pediatric Hematology Oncology Fellows. He currently mentors several recipients of career development grants.
    Dr. Lebensburger also serves as faculty at the American Society of Hematology Clinical Research Training Institute where he mentors young leaders in the field throughout the country.

    • Teaching Activities

    Education And Training

  • Arnold Palmer Children's Hospital, Internship
  • Arnold Palmer Children's Hospital, Residency
  • St. Jude Children's Research Hospital, Postdoctoral Fellowship
  • Doctor of Osteopathy in Osteopathic Medicine / Osteopathy, Nova Southeastern University 2003

    • Full Name

  • Jeffrey Lebensburger